AnaptysBio, Inc. (ANAB) 追踪市盈率为负值 -137.7, 表示公司目前在过去十二个月 (TTM) 基础上处于亏损状态。 前瞻市盈率 23.0 基于分析师预估，预计将恢复盈利。 追踪盈利收益率为 -0.73%, 前瞻盈利收益率 4.36%.
本页证实的标准:
SharesGrow 综合评分： 50/100 其中 3/7 项标准通过。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | -10.5 | 0.27 | 1.14 | 2.69 | - |
| 2017 | -66.3 | -0.12 | 6.48 | 199.24 | - |
| 2018 | -25.5 | -0.40 | 3.24 | 314.78 | - |
| 2019 | -4.5 | -0.10 | 1.09 | 54.96 | - |
| 2020 | -29.5 | 0.37 | 1.48 | 7.83 | - |
| 2021 | -16.5 | -0.09 | 2.67 | 15.09 | - |
| 2022 | -6.8 | -0.06 | 3.33 | 84.85 | - |
| 2023 | -3.5 | -0.11 | 6.55 | 33.61 | - |
| 2024 | -2.6 | 0.16 | 5.30 | 4.12 | - |
| 2025 | -101.8 | 1.12 | 36.21 | 5.74 | - |
| Year | EPS（稀释） | 营收 | 净利润 | 净利润率 |
|---|---|---|---|---|
| 2016 | $-0.23 | $16.68M | $-4.26M | -25.5% |
| 2017 | $-1.52 | $10M | $-30.07M | -300.7% |
| 2018 | $-2.50 | $5M | $-61.66M | -1233.1% |
| 2019 | $-3.60 | $8M | $-97.34M | -1216.7% |
| 2020 | $-0.73 | $75M | $-19.92M | -26.6% |
| 2021 | $-2.08 | $63.18M | $-57.19M | -90.5% |
| 2022 | $-4.57 | $10.29M | $-128.72M | -1251.3% |
| 2023 | $-6.08 | $17.16M | $-163.62M | -953.7% |
| 2024 | $-5.12 | $91.28M | $-145.23M | -159.1% |
| 2025 | $-0.46 | $234.6M | $-13.23M | -5.6% |
| Year | EPS（平均） | EPS 范围 | 营收（平均） | 营收范围 | 分析师人数 |
|---|---|---|---|---|---|
| 2026 | $-3.94 | $-8.63 – $1.43 | $111.27M | $60.31M – $211.93M | 7 |
| 2027 | $-3.83 | $-11.33 – $2.64 | $157.1M | $66.53M – $277.53M | 7 |
| 2028 | $-0.34 | $-1.83 – $1.28 | $265.34M | $261.52M – $269.15M | 7 |
| 2029 | $0.20 | $0.03 – $0.37 | $324.67M | $117.75M – $546.2M | 2 |
| 2030 | $4.06 | $0.70 – $7.67 | $489.58M | $177.56M – $823.62M | 5 |
